ArticleMolecular biology reports2026
Potential anti-inflammatory effect of L-carvone in endothelial dysfunction triggered by uremia related to chronic kidney disease.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is one of the leading causes of endothelial dysfunction and directly associated with the development of cardiovascular diseases (CVD). The accumulation of uremic toxins stimulates development of an exacerbated inflammatory state, especially in the vascular endothelial microenvironment. L-carvone (CRV) monoterpene is a natural product with several described biological activities, including atheroprotective and anti-inflammatory effects. This study aimed to investigate the in vitro anti-inflammatory effect of CRV on human endothelial cells exposed to hemodialysis patients' serum. METHODS AND
resultsCRV did not affect endothelial cell viability at a concentration of 100 µM, either alone or in combination with uremic serum (US), but it induced a significant increase in cell proliferation (P < 0.05). CRV significantly reduced the gene (P < 0.05) and protein (P < 0.01) expression of Interleukin (IL) 1β (IL-1β) under uremic conditions. CRV also significantly decreased protein levels of other inflammatory biomarkers such as IL-6, IL-8, vascular endothelial growth factor (VEGF-A), serum amyloid A (SAA) (P < 0.01) and tumor necrosis factor α (TNF-α) (P < 0.05) in uremic conditions. Monocyte chemoattractant protein 1 (MCP-1) production was additionally reduced (P < 0.01) and consequently monocyte migration was reduced (P < 0.05) with CRV under uremic conditions. Cell morphology appeared to remain unchanged in the presence of CRV, and it reduced the cellular damage in the uremic environment caused by uremia.
conclusionsAltogether, these findings suggest the beneficial anti-inflammatory effect of CRV in the vascular environment in response to uremic damage in CKD patients, opening perspectives for the study of new targets to better understand the endothelial protection mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.